Evotec's Half-Year Numbers Land With a Thud, Yet One Analyst Sees a 10-Euro Prize

Evotec's H1 revenue fell 19.2% to €300.1M, adjusted EBITDA loss widened to €42.7M, and shares slid 5.1% despite reaffirmed guidance.

The market's verdict on Evotec's first-half results was swift and unforgiving, even though the figures themselves carried little surprise. Shares in the Hamburg-based drug discovery specialist slid 5.1% on Thursday to €3.62, erasing a modest short-term bounce that had offered holders a sliver of hope.

That fleeting recovery — a 10% gain over the preceding seven trading sessions — now looks like a footnote. The stock sits roughly 20% above the 52-week low of €3.19 touched in July, but remains a long way from the €7.75 peak reached in early November. Year-to-date, the equity is down 34%, with the twelve-month decline stretching to 42%.

Revenue Slide Accelerates as Losses Deepen

The numbers behind Thursday's sell-off paint a sobering picture. Group revenue for the first half of 2026 came in at €300.1 million, a 19.2% contraction from roughly €371 million in the prior-year period. The second quarter alone saw turnover fall 16.2% to €143.5 million, down from €171.2 million a year earlier.

Profitability tells an even bleaker story. Adjusted EBITDA for the April-to-June period swung to minus €20.8 million, compared with minus €5.0 million in the same quarter of 2025. For the full half-year, adjusted Group EBITDA landed at minus €42.7 million.

Management reaffirmed the sharply reduced guidance first flagged in July, sticking with a full-year revenue range of €570 million to €610 million and an adjusted EBITDA loss of between €70 million and €105 million. That represents a dramatic downgrade from the original 2026 outlook of €700 million to €780 million in sales, a cut the company attributed to deferred milestone payments and weaker contributions from newly signed partnerships.

A Familiar Story, Two Very Different Readings

What makes Thursday's trading action notable is the divergence between the market's reaction and the view from at least one major sell-side house. RBC analyst Charles Weston kept his "Outperform" rating and €10 price target intact, arguing that the quarterly figures merely confirmed the preliminary data released in July and therefore warranted no significant price movement.

The actual trading session told a different story, with investors choosing to focus on the widening operational losses rather than the absence of fresh negative surprises. The gap between RBC's €10 target and the current share price — a chasm of roughly 176% — underscores just how far apart fundamental assessment and market sentiment have drifted.

Retail investors have been vocal in their frustration, with online forums bristling over the lowered guidance and what many perceive as delayed partnership closures. The central question hanging over the stock: does the current operational pain mark a transitional phase, or does it reveal structural cracks in the core business?

Restructuring and New Alliances Offer a Counter-Narrative

Against this difficult backdrop, Evotec is pressing ahead with its "Horizon" restructuring programme, launched in March. The plan envisions cutting up to 800 jobs and consolidating the company's global footprint from 14 sites to 10 by the end of 2027, with annual cost savings of €75 million projected. Whether those savings will be sufficient to offset the current losses remains an open question.

On the growth front, management is betting on fresh research collaborations to rebuild the pipeline. Early August brought news of an AI-powered R&D partnership with Odyssey Therapeutics focused on identifying small molecules for autoimmune and inflammatory diseases. Such deals are intended to open new revenue streams over the medium term, though they are unlikely to close the current sales gap anytime soon.

Liquidity Provides a Cushion, But Time Is of the Essence

One bright spot: Evotec ended June with €465.6 million in liquidity, offering a buffer that gives the company room to manoeuvre through its current difficulties. That cushion, combined with the restructuring savings and new partnerships, forms the basis of the bull case.

A recent automated performance check awarded the stock a "D-rating," citing a negative average annual return over the past decade — a reminder of the equity's long-term struggles, though hardly a reliable short-term signal.

For now, the market's patience is being tested. The company has delivered its reduced guidance; the question is whether it can deliver on it. With the stock trading at a fraction of its 52-week high and RBC's target implying substantial upside, the coming quarters will determine whether the optimists or the sceptics have read this story correctly. The trajectory of partnership announcements — and the timing of those deferred milestone payments — will likely be the deciding factor.